Pilatus Biosciences, a biopharmaceutical company developing novel metabolic checkpoint immunotherapies for liver and gastrointestinal cancers, today announced the Company will present new preclinical data on its lead product candidate, PLT012, in a poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, being held November 5-9, 2025 in National Harbor, Maryland.
“Immunometabolism is a key lever for overcoming resistance in solid tumors,” said Dr. Yi-Ru Yu, Lead Scientist at Pilatus Biosciences and presenting author. “Our preclinical results demonstrate that PLT012, a first-in-class anti-CD36 monoclonal antibody, exerts a dual mechanism of action by reprogramming immune-metabolic pathways—suppressing immunosuppressive Tregs while enhancing CD8⁺ T-cell responses in lipid-rich tumors. These combined effects have been shown to drive durable and superior anti-tumor efficacy across multiple cancer models, outperforming anti–PD-1/PD-L1 blockade and inducing long-lasting immune memory that sustains tumor control and protects against rechallenge.” Dr. Raven Lin, CEO of Pilatus Biosciences, added “Alongside a favorable GLP toxicology profile, these data support our planned Phase I study, with first patient in (FPI) targeted for Q1 2026.”
